Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐XL in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients
A better understanding of multiple myeloma (MM) biology has led to the development of novel therapies. However, MM is still an incurable disease and new pharmacological strategies are needed. Dinaciclib, a multiple cyclin‐dependent kinase (CDK) inhibitor, which inhibits CDK1, 2, 5 and 9, displays si...
Main Authors: | Manuel Beltrán‐Visiedo, Nelia Jiménez‐Alduán, Rosana Díez, Marta Cuenca, Andrea Benedi, Alfonso Serrano‐Del Valle, Gemma Azaceta, Luis Palomera, Victor Peperzak, Alberto Anel, Javier Naval, Isabel Marzo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-12-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.13522 |
Similar Items
-
Mitotic stress-induced secretome primes cancer cells to apoptosis and maximizes paclitaxel response in breast tumors when combined with BCL-xL-targeting BH3 mimetics
by: Steven Lohard, et al.
Published: (2020-05-01) -
Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
by: Enyuan Shang, et al.
Published: (2020-08-01) -
Study of the Bcl-2 Interactome by BiFC Reveals Differences in the Activation Mechanism of Bax and Bak
by: Óscar Gonzalo, et al.
Published: (2023-03-01) -
BH3-mimetics: recent developments in cancer therapy
by: Paul A. Townsend, et al.
Published: (2021-11-01) -
Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors
by: Viacheslav V. Senichkin, et al.
Published: (2021-12-01)